Showing 15 posts of 26 posts found.

Perrigo image

Perrigo acquires Omega for $4.5 billion

November 7, 2014
Manufacturing and Production, Sales and Marketing Actavis, Boehringer Ingelheim, Boehringer Ingelheim., Elan, Perrigo, Sanofi, omega

In a deal worth $4.5 billion Perrigo has announced the acquisition of over-the-counter (OTC) drugmaker Omega. This places the Irish …


Edelman buys Elan to ‘challenge’ the French PR industry

September 5, 2014
Medical Communications, Sales and Marketing Edelman, Elan, publicis

Edelman has swooped in on fellow PR firm Elan to create a ‘new player’ in the communications industry in France. …


Questcor adds Elan president to its Board

November 15, 2013
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Elan, Questcor, martin

Biopharma firm Questcor Pharmaceuticals has appointed Elan’s president and chief executive G. Kelly Martin to its Board of directors. Martin has …

Elan image

Perrigo pays $8.6 billion for Elan

July 30, 2013
Research and Development, Sales and Marketing Elan, Perrigo, Tysabri

Generics firm Perrigo has snapped up Ireland-based Elan in a multi-billion dollar deal, ending a bitter takeover battle that has …

J&J image

J&J sees Q2 sales rise

July 17, 2013
Sales and Marketing Elan, J&J, JJ, Q2, Synthes, sales

Johnson & Johnson saw overall sales rise 8.5% year-on-year in the second quarter of 2013, with the US healthcare group …

Elan image

Elan signs $1 billion finance deal with Theravance

May 15, 2013
Research and Development, Sales and Marketing Elan, Theravance, royalty pharma

Elan has struck a novel deal with Theravance which gives it a share of potential future royalties from its respiratory …

elan image

Elan sceptical of Royalty

February 26, 2013
Sales and Marketing Elan, FDA, Tysabri, royalty pharma

Elan Corporation has poured tepid water on private equity firm Royalty Pharma’s putative offer this week for the Irish biotech …

Tysabri image

Biogen and Elan file for Tysabri first line use in MS

January 18, 2013
Sales and Marketing Biogen IDEC, EMA, Elan, FDA, MS, Tsyabri, gilenya

Biogen Idec and Elan have applied to the FDA and EMA to expand Tysabri’s use in patients with relapsing forms …

Tsyabri image

Elan to spin off drug discovery arm

August 14, 2012
Research and Development, Sales and Marketing Elan, Neotype Biosciences, Tysabri, multiple sclerosis

Elan Corporation is to spin off its drug discovery arm Neotype Biosciences to create a separate, quoted company by the …

Lonza picture

Lonza to make Elan’s Alzheimer’s candidate

December 7, 2011
Manufacturing and Production Abbott, Elan, Lonza

Elan has awarded a manufacturing contract to Lonza to supply the active pharmaceutical ingredient (API) for its small-molecule candidate Alzheimer’s …

Alkermes and Elan Drug Technologies complete merger

September 19, 2011
Manufacturing and Production Alkermes, Elan, pharma manufacturing news

The contract manufacturing and development unit of Irish drugmaker Elan has completed a near-$1 billion merger with drug delivery specialist …

Elan signs $20m research deal with Proteostasis

May 25, 2011
Research and Development Elan, Proteostasis, neurodegenerative diseases

Elan Corporation has signed a deal with US small molecule drug specialist Proteostasis Therapeutics to develop products for conditions such …

Elan manufacturing

Elan sells formulations unit to Alkermes for $960m

May 10, 2011
Manufacturing and Production Alkermes, Elan

Irish drugmaker Elan has finally found a buyer for its Elan Drug Technologies unit, which has been on and off …


Pharmaceutical manufacturing news in brief

February 15, 2011
Manufacturing and Production Boehringer Ingelheim, DSM Biologics, Elan, Novasep

Irish drugmaker Elan has forged an alliance with Boehringer Ingelheim to develop and manufacture antibody-based therapeutics. Under the terms of …

Elan names Robert Ingram as new chairman

December 10, 2010
Research and Development, Sales and Marketing Elan, appointment, research and development, sales and marketing

Elan has appointed former Glaxo Wellcome chief executive Robert Ingram as its chairman-designate. Ingram led Glaxo between 1997 and 2000 …

Latest content